FDA Reviewing Safety Of Popular Weight-Loss Drug

Law360, New York (August 25, 2009, 7:54 PM EDT) -- The U.S. Food and Drug Administration has launched a safety review into versions of the popular weight-loss drug orlistat marketed by Roche Applied Science and GlaxoSmithKline after receiving adverse event reports.

Glaxo released Alli, a nonprescription version of the drug, in the U.S. in 2007, which was the first weight-loss pill to be approved by the FDA. Roche markets the prescription version, known as Xenical.

The FDA said Aug. 24 that it received 32 adverse event reports between 1999 and 2008 from users of Xenical and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.